Zobrazeno 1 - 10
of 179
pro vyhledávání: '"Kimberly L Blackwell"'
Autor:
Tammy J Westmoreland, Sajith M Wickramasekara, Andrew Y Guo, Alice L Selim, Tiffany S Winsor, Arno L Greenleaf, Kimberly L Blackwell, John A Olson, Jeffrey R Marks, Craig B Bennett
Publikováno v:
PLoS ONE, Vol 4, Iss 6, p e5830 (2009)
The chemotherapeutic doxorubicin (DOX) induces DNA double-strand break (DSB) damage. In order to identify conserved genes that mediate DOX resistance, we screened the Saccharomyces cerevisiae diploid deletion collection and identified 376 deletion st
Externí odkaz:
https://doaj.org/article/7e3c66acc2fb4792a627abbf418cf73e
Autor:
Carey K Anders, Chaitanya R Acharya, David S Hsu, Gloria Broadwater, Katherine Garman, John A Foekens, Yi Zhang, Yixin Wang, Kelly Marcom, Jeffrey R Marks, Sayan Mukherjee, Joseph R Nevins, Kimberly L Blackwell, Anil Potti
Publikováno v:
PLoS ONE, Vol 3, Iss 1, p e1373 (2008)
To define the biology driving the aggressive nature of breast cancer arising in young women.Among 784 patients with early stage breast cancer, using prospectively-defined, age-specific cohorts (young or=65 years), 411 eligible patients (n = 200or=65
Externí odkaz:
https://doaj.org/article/82417eaf3e2840f3a35099957d5cd982
Autor:
John H. Strickler, Christel N. Rushing, Donna Niedzwiecki, Abigail McLeod, Ivy Altomare, Hope E. Uronis, S. David Hsu, S. Yousuf Zafar, Michael A. Morse, David Z. Chang, James L. Wells, Kimberly L. Blackwell, P. Kelly Marcom, Christy Arrowood, Emily Bolch, Sherri Haley, Fatima A. Rangwala, Ace J. Hatch, Andrew B. Nixon, Herbert I. Hurwitz
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background Patients with chemotherapy refractory metastatic colorectal cancer (CRC) have a poor prognosis and limited therapeutic options. In this phase Ib/II clinical trial, we established the maximum tolerated dose (MTD) and recommended ph
Externí odkaz:
https://doaj.org/article/cee4dcf4fc8d4276878e7ac77b99ef23
Autor:
Kimberly L. Blackwell, Sarah Bacus, Renee A. Welch, Erika Hamilton, Justin Favaro, Gretchen G. Kimmick, Judith Hopkins, P. Kelly Marcom, Bercedis L. Peterson, Vijaya Chadaram, Christina I. Herold
XLS file - 16K, Pulmonary and pleural effusions, pneumonitis.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5bf3beb80e1a37fabde4ae5b4ab567b
https://doi.org/10.1158/1078-0432.22444086
https://doi.org/10.1158/1078-0432.22444086
Autor:
Kimberly L. Blackwell, Sarah Bacus, Renee A. Welch, Erika Hamilton, Justin Favaro, Gretchen G. Kimmick, Judith Hopkins, P. Kelly Marcom, Bercedis L. Peterson, Vijaya Chadaram, Christina I. Herold
Purpose: A phase II study of dasatinib, an inhibitor of multiple oncogenic tyrosine kinases including Src, was conducted to evaluate 16-week progression-free rate and tolerability in patients with previously treated metastatic breast cancer (MBC). Re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35626b66f610a4abdadbd2105d7447df
https://doi.org/10.1158/1078-0432.c.6520056
https://doi.org/10.1158/1078-0432.c.6520056
Autor:
Rebecca G. Bagley, Denise A. Yardley, Volker Möbus, Abdel-Baset Halim, Rita Nanda, Gail S. Wright, Andres Forero-Torres, Thomas Hawthorne, Javier Cortes, Alberto J. Montero, Linda T. Vahdat, Kimberly L. Blackwell, Michelle E. Melisko, Melinda L. Telli, Yi He, Peter Schmid, Cynthia X. Ma, Christopher D. Turner
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-10 (2021)
Scientia
NPJ Breast Cancer
Scientia
NPJ Breast Cancer
Breast cancer; Cancer Càncer de mama; Càncer Cáncer de mama; Cáncer The METRIC study (NCT#0199733) explored a novel antibody–drug conjugate, glembatumumab vedotin (GV), targeting gpNMB that is overexpressed in ~40% of patients with triple-negat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92ba4d4292b16f0be2f40ca88020f4d3
https://doaj.org/article/17180d15d53a444b97cb83ce78fb7480
https://doaj.org/article/17180d15d53a444b97cb83ce78fb7480
Autor:
Nike Beaubier, Aneta Piwowarczyk, Minetta C. Liu, Jeff Schaffer, Kimberly L. Blackwell, Ben Park
Publikováno v:
Cancer Research. 81:PD9-12
Genomic testing has transformed clinical care in metastatic breast cancer. Cell-free DNA (cfDNA) has made sequential testing feasible, however, concordance between tissue and cfDNA, sensitivity of cfDNA, and optimal sampling frequency have not been e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ea84b32ec016ebfce659d9072dd595f9
https://doi.org/10.1158/1538-7445.sabcs20-pd9-12
https://doi.org/10.1158/1538-7445.sabcs20-pd9-12
Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines
Autor:
Timothy A. Yap, Arya Ashok, Jessica Stoll, Elizabeth Mauer, Vanessa M. Nepomuceno, Kimberly L. Blackwell, Judy E. Garber, Funda Meric-Bernstam
Publikováno v:
JAMA network open. 5(5)
Germline testing guidelines are suggested for specific disease types or a family history of cancer, yet alterations are found in cancer types in which germline testing is not routinely indicated. The clinical role of identifying germline variants in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4511d3bcf2f40d7d167cfa6187c5b54
https://pubmed.ncbi.nlm.nih.gov/35594050
https://pubmed.ncbi.nlm.nih.gov/35594050
Autor:
Minetta C. Liu, Matthew MacKay, Matthew Kase, Aneta Piwowarczyk, Christine Lo, Jeff Schaeffer, Justin D. Finkle, Christopher E. Mason, Nike Beaubier, Kimberly L. Blackwell, Ben Ho Park
Publikováno v:
JCO precision oncology. 6(1)
PURPOSE Tissue-based next-generation sequencing (NGS) in metastatic breast cancer (mBC) is limited by the inability to noninvasively track tumor evolution. Cell-free DNA (cfDNA) NGS has made sequential testing feasible; however, the relationship betw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc590eed5a186aa9560aad7496027350
https://pubmed.ncbi.nlm.nih.gov/35721584
https://pubmed.ncbi.nlm.nih.gov/35721584
Autor:
Ace J. Hatch, Christel Rushing, Emily Bolch, Hope E. Uronis, S. David Hsu, James Leroy Wells, Abigail B. McLeod, Donna Niedzwiecki, Christy Arrowood, Kimberly L. Blackwell, John H. Strickler, P. Kelly Marcom, S. Yousuf Zafar, Michael A. Morse, Herbert Hurwitz, Ivy Altomare, Sherri Haley, Andrew B. Nixon, Fatima A. Rangwala, David Z. Chang
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
BMC Cancer
BMC Cancer
Background Patients with chemotherapy refractory metastatic colorectal cancer (CRC) have a poor prognosis and limited therapeutic options. In this phase Ib/II clinical trial, we established the maximum tolerated dose (MTD) and recommended phase II do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::544ae352d7f5233576a777ba7b6f4aa4
http://link.springer.com/article/10.1186/s12885-019-6234-8
http://link.springer.com/article/10.1186/s12885-019-6234-8